Sigilon Therapeutics slides on more bad news from on-hold drug trial

Sigilon Therapeutics

29/11/2021 12:45

** Shares of drug developer  SGTX.O  slide 10% premarket to
$3.55 - lowest since debuting almost a year ago 
    ** Co says fibrosed spheres were observed during retrieval
of implanted spheres in a patient in an early-stage trial of
co's experimental therapy, SIG-001, for blood disorder
hemophilia  urn:newsml:reuters.com:*:nFWN2SK0FH
    ** Fibrosis is the formation of an abnormal amount of
fibrous tissue in an organ or part 
    ** Co's shares had plunged in July when the SIG-001 trial
had been placed on hold due to an adverse event  urn:newsml:reuters.com:*:nL3N2OL2WB
    ** Says findings may impact timing of the planned
early-stage trial of its drug, SIG-005, for
mucopolysaccharidosis type I, a metabolic disorder
    ** Status of Sigilon's clinical hold investigation for
SIG-001, including the latest findings, will be reviewed by the
Safety Review Committee at its next meeting in December
    ** Shares set to extend losses to s sixth straight session 
    ** SGTX down ~92% YTD as of last close

 (Reporting by Susan Mathew)
 ((susan.mathew@thomsonreuters.com))